Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Issue 2 (16th February 2022)

• Record Type: Journal Article
• Authors: Cortellini, Alessio; Ricciuti, Biagio; Vaz, Victor R; Soldato, Davide; Alessi, Joao V; Dall'Olio, Filippo G; Banna, Giuseppe L; Muthuramalingam, Sethupathi; Chan, Samuel; Majem, Margarita; Piedra, Aida; Lamberti, Giuseppe; Andrini, Elisa; Addeo, Alfredo; Friedlaender, Alex; Facchinetti, Francesco; Gorría, Teresa; Mezquita, Laura; Hoton, Delphine; Valerie, Lacroix; Nana, Frank Aboubakar; Artingstall, James; Comins, Charles; Di Maio, Massimo; Caglio, Andrea; Cave, Judith; McKenzie, Hayley; Newsom-Davis, Thomas; Evans, Joanne S; Tiseo, Marcello; D'Alessio, Antonio; Fulgenzi, Claudia A M; Besse, Benjamin; Awad, Mark M; Pinato, David J;
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 2(2022)
• Publication Date: 2022-02-16
• Subjects: immunity -- lung neoplasms -- programmed cell death 1 receptor -- metabolic networks and pathways; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2021-004374
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Introduction: It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations. Methods: In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria. Results: Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p<0.0001), with better baseline Eastern Cooperative Oncology Group—Performance Status (p=0.0127), and had lower prevalence of central nervous system (p=0.0002) and liver metastases (p=0.0395). Univariable analyses showed a significant difference in the median OS across underweight (15.5 months), normal weight (14.6 months), overweight (20.9 months), and obese (16.8 months) patients (log-rank: p=0.045, log rank test for trend: p=0.131), while no difference was found with respect to the median PFS (log-rank for trend: p=0.510). Neither OS nor PFS was significantly associated with baseline BMI on multivariable analysis. Conclusions: In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC.